Contact information
Research groups
Gusztav Milotay
DPhil Student
Prior to starting a DPhil, I worked in a TCR therapeutics company called Etcembly where I contributed to the development of a microfluidics platform for peripheral immune repertoire sequencing. I am now looking to expand on single cell approaches to try and deorphanise TCRs in melanoma patients who respond to checkpoint immunotherapy and potentially leverage this to probe the relationship between response and toxicity.
Recent publications
-
Cytomegalovirus infection protects against metastatic melanoma and modulates oncological outcome and toxicity to checkpoint immunotherapy
Preprint
Milotay G. et al, (2024)